Combination therapy for liver cancer with blood vessel involvement
Part of Cancer, Digestive system clinical trials.
This trial tests a combination treatment for liver cancer that can be surgically removed but has started growing into nearby blood vessels. The goal is to see if the combination helps control the disease before or after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with liver cancer (hepatocellular carcinoma) that can be removed with surgery.
- The cancer must have grown into blood vessels near the liver, but not spread to other parts of the body and not in the main portal vein.
- You must not have had any prior treatment for liver cancer, like chemotherapy, targeted therapy, or immunotherapy.
- Your liver function must be good (Child-Pugh class A) and you must be generally active and able to care for yourself.
- Your blood counts and kidney function need to be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Liver Cancer (Primary and Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.